Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이순남 | - |
dc.date.accessioned | 2016-08-27T02:08:02Z | - |
dc.date.available | 2016-08-27T02:08:02Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.other | OAK-1969 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/215734 | - |
dc.description.abstract | Purpose Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer. Materials and Methods One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m(2)) or cisplatin (60 mg/m(2)) was given over 1 hour with 5-FU (1 gm/m(2)) on days 1 similar to 5 every 4 weeks. Results At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3 similar to 4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths. Conclusion Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities. | - |
dc.language | English | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | Combination chemotherapy | - |
dc.subject | Advanced gastric cancer | - |
dc.subject | Heptaplatin | - |
dc.title | Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer | - |
dc.type | Article | - |
dc.relation.issue | 1 | - |
dc.relation.volume | 41 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.index | KCI | - |
dc.relation.startpage | 12 | - |
dc.relation.lastpage | 18 | - |
dc.relation.journaltitle | CANCER RESEARCH AND TREATMENT | - |
dc.identifier.doi | 10.4143/crt.2009.41.1.12 | - |
dc.identifier.wosid | WOS:000208486400002 | - |
dc.author.google | Lee, Kyung Hee | - |
dc.author.google | Hyun, Myung Soo | - |
dc.author.google | Kim, Hoon-Kyo | - |
dc.author.google | Jin, Hyung Min | - |
dc.author.google | Yang, Jinmo | - |
dc.author.google | Song, Hong Suk | - |
dc.author.google | Do, Young Rok | - |
dc.author.google | Ryoo, Hun Mo | - |
dc.author.google | Chung, Joo Seop | - |
dc.author.google | Zang, Dae Young | - |
dc.author.google | Lim, Ho-Yeong | - |
dc.author.google | Jin, Jong Youl | - |
dc.author.google | Yim, Chang Yeol | - |
dc.author.google | Park, Hee Sook | - |
dc.author.google | Kim, Jun Suk | - |
dc.author.google | Sohn, Chang Hak | - |
dc.author.google | Lee, Soon Nam | - |
dc.contributor.scopusid | 이순남(8422735900;56949372000) | - |
dc.date.modifydate | 20220112143047 | - |